Can Frailty and Other Factors, as Estimated by HU, Predict Response to Anabolic Bone Medications?

Disclosure(s):

Benjamin Elder, MD, PhD: InjectSense: Advisor (Ongoing), Stock Options (Ongoing), Stock Shareholder (excluding mutual funds) (Ongoing); Iota Biosciences: Consultant (Terminated, November 1, 2024); J&J MedTech: Consultant (Ongoing); SI BONE: Consultant (Ongoing), Grant/Research Support (Ongoing), Royalty Recipient (Ongoing); Stryker (K2M): Grant/Research Support (Ongoing)